对轴性脊椎关节炎的药物治疗方法的进展
Eric Toussirot1,2,3,4
1Département Universitaire de Thérapeutique, Université de Franche-Comté, Besançon, France.
Expert opinion on pharmacotherapy
|June 15, 2023
概括
非类固醇抗炎药物 (NSAIDs) 是轴性脊柱关节炎 (axSpA) 的第一线治疗方法. 像TNF抑制剂和IL-17抑制剂这样的生物药物是后续的选择,JAK抑制剂用于特定的放射性axSpA患者.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 轴性脊椎关节炎 (axSpA) 是一种炎症性疾病,影响脊椎和关节.
- 它呈现在放射性 (r-axSpA) 和非放射性 (nr-axSpA) 形式,影响移动性和生活质量.
研究的目的:
- 审查 axSpA.目前的非药物和药物治疗选择.
- 评估NSAIDs,生物药物 (TNF抑制剂,IL-17抑制剂) 和Janus激酶抑制剂的作用.
主要方法:
- 使用PubMed搜索进行文献综述.
- 对治疗指南和临床试验数据的分析.
主要成果:
- 无抗炎药物是axSpA的主要初始治疗方法.
- TNF抑制剂和IL-17抑制剂是有效的生物治疗方法,选择受关节外表现的影响.
- 雅努斯激酶抑制剂是对特定患者的r-axSpA的新选择.
结论:
- 对于 axSpA.存在标准化的治疗管理.
- 治疗的选择取决于疾病的形式,患者的形状和关节外疾病的存在.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
01:28Drug Therapy
74
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
74
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
01:29Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179